
WHAT IS CLAIMED:


1. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 6), or a salt thereof.

2. The modified oligonucleotide of claim 1, wherein the modified oligonucleotide is the sodium salt or the potassium salt.

3. A modified oligonucleotide according to the following chemical structure:



(SEQ ID NO: 6).

4. A composition comprising the modified oligonucleotide of any one of claims 1-3, and a pharmaceutically acceptable diluent or carrier.

5. A composition comprising the modified oligonucleotide of any one of claims 1-3, and water.

6. Use of the modified oligonucleotide of any one of claims 1-3 in the manufacture of a medicament for treating, preventing or ameliorating a cancer.

7. The use of claim 6, wherein the cancer is cancer associated with MALAT1.

8. The use of claim 6 or 7, wherein the cancer is breast cancer; inflammatory breast cancer; breast ductal carcinoma; breast lobular carcinoma; luminal A breast cancer; luminal B breast cancer; basal-like breast cancer; HER2 positive (HER2+) breast cancer; HER2 negative (HER2-) breast cancer; Estrogen Receptor negative (ER-) breast cancer; Estrogen Receptor positive (ER+) breast cancer; Progesterone Receptor negative (PR-) breast cancer; Progesterone Receptor positive (PR+) breast cancer; ER positive (ER+) and PR positive (PR+) breast cancer; ER positive (ER+) and PR negative (PR-) breast cancer; ER negative (ER-) and PR

positive (PR+) breast cancer; ER positive (ER+) and HER2 negative (HER2-) breast cancer; ER-, PR-, and HER2- triple negative breast cancer (ER-, PR-, HER2-; TNBC); hormone receptor negative breast cancer (ER- and PR-); ER+, PR+, and HER2+ triple positive breast cancer (ER+, PR+, HER2+; TPBC); hepatocellular carcinoma (HCC); head and neck squamous cell carcinoma (HNSCC); oral tongue squamous cell carcinoma (OTSCC); sarcomas (e.g. epitheloid, rhabdoid and synovial); esophageal cancer; gastric cancer; ovarian cancer; pancreatic cancer; lung cancer; non-small cell lung carcinoma (NSCLC); small-cell lung carcinoma (SCLC); squamous cell carcinoma (SCC); head and neck cancer; head and neck squamous cell carcinoma (HNSCC); gastrointestinal cancer; large intestinal cancer; small intestinal cancer; stomach cancer; colon cancer; colorectal cancer; bladder cancer; liver cancer; biliary tract cancer; urothelial cancer; endometrial cancer; cervical cancer; prostate cancer; mesothelioma; chordoma; renal cancer; renal cell carcinoma (RCC); brain cancer; neuroblastoma; glioblastoma; skin cancer; melanoma; basal cell carcinoma; merkel cell carcinoma; blood cancer; hematopoetic cancer; myeloma; multiple myeloma (MM); B cell malignancies; lymphoma; B cell lymphoma; Hodgkin lymphoma; T cell lymphoma; leukemia; or acute lymphocytic leukemia (ALL).

9. The use of any one of claims 6-8, wherein the modified oligonucleotide is to be administered parenterally.

10. The use of any one of claims 6-9, wherein the modified oligonucleotide inhibits or reduces cancer cell proliferation, cancer cell migration, cancer cell branching morphogenesis, tumor progression, tumor growth, or metastasis.

11. The use of any one of claims 6-10, wherein the modified oligonucleotide increases or induces cancer cell differentiation, cancer cell adhesion, or tumor differentiation.

12. The use of any one of claims 6-11, wherein the modified oligonucleotide induces a cancer cell or tumor to have a cystic, ductular, or acinar phenotype or morphology.

13. The use of any one of claims 6-12, wherein the modified oligonucleotide induces a cancer cell or tumor to have a more differentiated phenotype or structure.

14. The use of claim 13, wherein the more differentiated phenotype or structure comprises presence of secretory lipid droplets, increased desmosomal structures, polarized ductal structures, or increased levels of E-cadherin or casein.

15. Use of the modified oligonucleotide of any one of claims 1-3 in the manufacture of a medicament for

inhibiting expression of MALAT1 in a cancer cell;

reducing or inhibiting cancer cell proliferation, cancer cell migration, cancer cell branching morphogenesis, tumor progression, tumor growth, or metastasis in an individual having cancer;

increasing or inducing cancer cell differentiation, cancer cell adhesion, or tumor differentiation in an individual having cancer;

inducing a cancer cell or tumor to have a cystic, ductular, or acinar phenotype or morphology in an individual; or

inducing a cancer cell or tumor to have a more differentiated phenotype or structure, optionally wherein the more differentiated phenotype or structure comprises presence of secretory lipid droplets, increased desmosomal structures, polarized ductal structures, or increased levels of E-cadherin or casein.

16. The modified oligonucleotide of any one of claims 1-3 for use in therapy.